Literature DB >> 2155116

Interleukin 4 activates human B lymphocytes via transient inositol lipid hydrolysis and delayed cyclic adenosine monophosphate generation.

M Finney1, G R Guy, R H Michell, J Gordon, B Dugas, K P Rigley, R E Callard.   

Abstract

We report from three independent centers that, in human tonsillar B lymphocytes, human IL4 switches on a series of second messenger changes, the precise sequence of which constitutes a novel signal transduction cascade. It involves an immediate and transient elevation of inositol 1,4,5-trisphosphate and Ca2+ levels. This is followed several minutes later by a sustained rise in cellular cyclic adenosine monophosphate concentration, the triggering of which involves both the Ca2+ rise and an additional, as yet unidentified, IL4-generated signal. Both the products of the initial inositol lipid hydrolysis and the delayed cyclic adenosine monophosphate accumulation are essential for the later induction of CD23 expression, a major phenotypic change promoted in these cells by IL4. The striking contrast between these findings and those that have been observed for the IL4 triggering of murine B cells is discussed.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2155116     DOI: 10.1002/eji.1830200122

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  17 in total

Review 1.  Cytokines in asthma.

Authors:  K F Chung; P J Barnes
Journal:  Thorax       Date:  1999-09       Impact factor: 9.139

2.  A microfilament formation inhibitor, cytochalasin strongly enhances the low-affinity Fc epsilon receptor II (CD23) expression on the human monocyte-like cell line, U937.

Authors:  N Ikewaki; H Tamauchi; A Yamada; M Aoki; R Yamamoto; A Sawada; H Inoko
Journal:  J Clin Immunol       Date:  2000-11       Impact factor: 8.317

3.  Responsiveness of human neutrophils to interleukin-4: induction of cytoskeletal rearrangements, de novo protein synthesis and delay of apoptosis.

Authors:  D Girard; R Paquin; A D Beaulieu
Journal:  Biochem J       Date:  1997-07-01       Impact factor: 3.857

Review 4.  Cytokine receptors: structure and signal transduction.

Authors:  B M Foxwell; K Barrett; M Feldmann
Journal:  Clin Exp Immunol       Date:  1992-11       Impact factor: 4.330

5.  Focused transcription from the human CR2/CD21 core promoter is regulated by synergistic activity of TATA and Initiator elements in mature B cells.

Authors:  Rhonda L Taylor; Mark N Cruickshank; Mahdad Karimi; Han Leng Ng; Elizabeth Quail; Kenneth M Kaufman; John B Harley; Lawrence J Abraham; Betty P Tsao; Susan A Boackle; Daniela Ulgiati
Journal:  Cell Mol Immunol       Date:  2015-02-02       Impact factor: 11.530

Review 6.  Cellular signalling mechanisms in B lymphocytes.

Authors:  W Cushley; M M Harnett
Journal:  Biochem J       Date:  1993-06-01       Impact factor: 3.857

7.  Identification of a cDNA for a human high-molecular-weight B-cell growth factor.

Authors:  J L Ambrus; J Pippin; A Joseph; C Xu; D Blumenthal; A Tamayo; K Claypool; D McCourt; A Srikiatchatochorn; R J Ford
Journal:  Proc Natl Acad Sci U S A       Date:  1993-07-01       Impact factor: 11.205

8.  Inhibition by glucocorticoid and staurosporine of IL-4-dependent CD23 production in B lymphocytes is reversed on engaging CD40.

Authors:  A Katira; K A Knox; M Finney; R H Michell; M Wakelam; J Gordon
Journal:  Clin Exp Immunol       Date:  1993-05       Impact factor: 4.330

9.  Treatment in vitro of retinal cells with IL-4 increases the survival of retinal ganglion cells: the involvement of BDNF.

Authors:  Leandro de Araujo-Martins; Raphael Monteiro de Oliveira; Gabriela Velozo Gomes dos Santos; Renata Cláudia Celestino dos Santos; Aline Araujo dos Santos; Elizabeth Giestal de Araujo
Journal:  Neurochem Res       Date:  2012-10-16       Impact factor: 3.996

10.  Interleukin-4 suppression of monocyte tumour necrosis factor-alpha production. Dependence on protein synthesis but not on cyclic AMP production.

Authors:  P H Hart; C A Jones; J J Finlay-Jones
Journal:  Immunology       Date:  1992-08       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.